Latest chemotherapy Stories
PALO ALTO, Calif., May 22, 2013 /PRNewswire/ -- Cellular Biomedicine Group (OTCQB: CBMG) today announced that it has achieved half of the enrollment of the total projected enrollment required for its Phase I trial to evaluate the safety and preliminary efficacy of TC-DC (Tumor Stem Cell Specific Dendritic Cell) therapy for hepatocellular carcinoma (HCC), the most common type of liver cancer. To date the trial has had no Severe Adverse Effect (SAE) reported. The Phase I clinical trial...
STOCKHOLM, May 21, 2013 /PRNewswire/ -- Oncopeptides AB, a company working to enhance oncology therapies, today announced the conclusion of a series A financing round intended to fund the phase II program. HealthCap led the investment with support from the long-term investor Industrifonden; members of Oncopeptides' management and Board also participated in the round. (Logo: http://photos.prnewswire.com/prnh/20130521/613959 ) The investment will finance a phase...
NPAF Urges N.C. Senate to Protect Patients from High Out of Pocket Costs RALEIGH, N.C., May 16, 2013 /PRNewswire-USNewswire/ -- Today, the National Patient Advocate Foundation acknowledges that the North Carolina House of Representatives recently approved a bill that would prohibit insurers who offer coverage for chemotherapy from charging patients higher out-of-pocket fees for newer, more expensive oral anti-cancer drugs than for IV formularies, many of which have more severe...
Data Presented at American Society of Clinical Oncology (ASCO) on two Boehringer Ingelheim Phase III Oncology Compounds, Afatinib* and Nintedanib*, Show Progression Free Survival in Patients with Advanced Non-Small Cell Lung Cancer BURLINGTON, ON, May 16, 2013 /CNW/ - New research taking place right here on Canadian soil is shedding light on the nation's number one cancer killer,(i) lung cancer. Boehringer Ingelheim (Canada) Ltd. today announced data from Phase III clinical...
Data to Be Presented at Annual Meeting of the American Society of Clinical Oncology (ASCO) LUGANO, Switzerland and WOODCLIFF LAKE, N.J., May 16, 2013 /PRNewswire/ -- Helsinn Group and Eisai Inc. announced today top-line results from Helsinn's pivotal clinical studies investigating the oral fixed-dose combination of netupitant and palonosetron (NEPA) being evaluated for the proposed indication of prevention of chemotherapy-induced nausea and vomiting (CINV). These data will be...
Spring dedication at Huntsville Botanical Garden displays new gardens symbolizing hope and courage in the fight against cancer HUNTSVILLE, Ala., May 14, 2013 /PRNewswire/ -- One brave woman currently undergoing chemotherapy and two cancer survivors, their families, friends and members of the Huntsville community celebrated life today at the Intergraph(® )Garden of Hope spring dedication in a poignant display of inspiration at the Huntsville Botanical Garden. (Logo:...
New legislation in the House of Representatives, HR 1801, The Cancer Drug Coverage Parity Act seeks to require insurance companies to cover all intravenous and oral chemotherapy forms equally, potentially broadening access and availability to patients who need it. Seattle, WA (PRWEB) May 13, 2013 The Chris Elliott Fund commends the work of Congressman Brian Higgins, NY-26 , for introducing the Cancer Drug Coverage Parity Act which would require health insurance companies to equally cover...
Surviving Mesothelioma Reports that a study in Italy contains some potential good news for mesothelioma patients. Raleigh, N.C. (PRWEB) May 09, 2013 Surviving Mesothelioma Reports that a study in Italy contains some potential good news for mesothelioma patients. Researchers believe they have found a way to boost the effectiveness of chemotherapy for mesothelioma. Mesothelioma is an aggressive malignancy affecting the linings around organs. Along with surgery and sometimes radiotherapy,...
Because pregnant women and cancer patients share common safety concerns and experience many of the same skin conditions, the topical skin care products they desire are very similar. Pretty Mommies along with truespa Skin Care Center discuss the recent trend of maternity skin care being used by oncology patients. Orlando, FL (PRWEB) May 09, 2013 It is no surprise that pregnancy and nursing skin care products are held to a higher standard of safety. This is due to the fact that many...
Through the serendipity of science, researchers at the University of Pittsburgh have discovered a potential treatment for deadly, drug-resistant bacterial infections that uses the same approach that HIV uses to infect cells. The National Institutes of Health-supported discovery will be described in the June issue of the journal Antimicrobial Agents and Chemotherapy. It is especially promising in the development of a potential treatment for lung infections in people with cystic fibrosis....
Latest chemotherapy Reference Libraries
Intravenous therapy, commonly known as IV therapy, is known as the administration of a liquid substance directly into a vein. It is also known as drip therapy, because most often the liquid is suspended above the IV site by an infusion pump, and runs through a drip chamber, which prevents air from entering the line. IVs are the preferred method of drug administration in hospital settings because they are the fastest known route of getting medication to the body. Intravenous therapy can also...
Antiviral Chemistry & Chemotherapy is a peer-reviewed academic journal published bi-monthly by International Medical Press in London since 1997. When founded in January 1990, it was published by Blackwell Science. The current editor-in-chief is Hugh J. Field of University of Cambridge, UK. The journal publishes primary papers and reviews on all aspects of the preclinical development of antiviral agents, including their chemical synthesis, biochemistry, pharmacology, mode of action and...
